NAL ER IPF Respiratory Function and Safety Study

Completed · Phase 1 · Has a placebo group

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.

Key facts

Study ID
NCT07036029
Run by
Trevi Therapeutics
People needed
9
Starts
2025-08-21
Expected to finish
2026-06-30
Last updated by the study team
2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.